Douglas Kit Clary

US Patent:

6656465, Dec 2, 2003

Filed:

Jan 26, 2001

Appl. No.:

09/770949

Inventors:

Douglas O. Clary - San Francisco CA
Gisela Weskamp - New York NY
Leeann R. Austin - San Francisco CA
Louis F. Reichardt - San Francisco CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39395

US Classification:

4241301, 4241381, 4241411, 4241431, 4241561, 5303871, 5303881, 53038822

Abstract:

The use and production of immunoglobulins which activate trk receptors and imitate effects of neurotrophins are provided. Immunoglobulins which block trk receptor activation and methods of use are also provided.

US Patent:

6818440, Nov 16, 2004

Filed:

Apr 27, 1998

Appl. No.:

09/069228

Inventors:

Gregory D. Plowman - San Carlos CA
Douglas Clary - San Francisco CA

Assignee:

Sugen, Inc. - South San Francisco CA

International Classification:

C12N 1563

US Classification:

4353201, 4352523, 43525411, 435325, 536 231, 536 234, 536 235

Abstract:

The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.

US Patent:

7459156, Dec 2, 2008

Filed:

Aug 25, 2003

Appl. No.:

10/648619

Inventors:

Douglas O. Clary - San Francisco CA, US
Gisela Weskamp - New York NY, US
LeeAnn R. Austin - San Francisco CA, US
Louis F. Reichardt - San Francisco CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39/395
C07K 16/28

US Classification:

4241301, 4241411, 5303871, 5303881, 5303891

Abstract:

The use and production of immunoglobulins which activate trk receptors and imitate effects of neurotrophins are provided. Immunoglobulins which block trk receptor activation and methods of use are also provided.

US Patent:

20020068361, Jun 6, 2002

Filed:

Apr 7, 1998

Appl. No.:

09/057150

Inventors:

DOUGLAS CLARY - SAN FRANCISCO CA, US

International Classification:

G01N033/53
G01N033/567
C12N015/63
C12N015/85
C12N015/87

US Classification:

435/455000, 435/007100

Abstract:

The invention relates to methods of evaluating the specific function of a receptor protein tyrosine kinase in cells. The methods activate the receptor in a ligand independent fashion. In addition, the invention includes methods of identifying compounds that modulate receptor protein tyrosine kinase function.

US Patent:

20040219139, Nov 4, 2004

Filed:

May 20, 2004

Appl. No.:

10/849518

Inventors:

Gregory Plowman - San Carlos CA, US
Douglas Clary - San Francisco CA, US

Assignee:

SUGEN, INC.

International Classification:

A61K038/46
C07H021/04
C12N009/16

US Classification:

424/094600, 435/069100, 435/196000, 435/320100, 435/325000, 536/023200

Abstract:

The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.

US Patent:

20040234540, Nov 25, 2004

Filed:

May 20, 2004

Appl. No.:

10/849065

Inventors:

Gregory Plowman - San Carlos CA, US
Douglas Clary - San Francisco CA, US

Assignee:

SUGEN, INC.

International Classification:

A61K039/395
C07H021/04
C12N009/12

US Classification:

424/185100, 435/069100, 435/194000, 435/320100, 435/325000, 536/023200

Abstract:

The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.

US Patent:

20050026184, Feb 3, 2005

Filed:

May 20, 2004

Appl. No.:

10/849244

Inventors:

Gregory Plowman - San Carlos CA, US
Douglas Clary - San Francisco CA, US

International Classification:

C12Q001/68
G01N033/574
C07H021/04
C12N009/12

US Classification:

435006000, 435007230, 435069100, 435320100, 435194000, 435325000, 536023200

Abstract:

The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.

US Patent:

20060216730, Sep 28, 2006

Filed:

Dec 29, 2005

Appl. No.:

11/320072

Inventors:

Gregory Plowman - San Carlos CA, US
David Whyte - Belmont CA, US
Gerard Manning - South San Francisco CA, US
Sucha Sudarsanam - South San Francisco CA, US
Ricardo Martinez - Foster City CA, US
Peter Flanagan - San Francisco CA, US
Douglas Clary - South San Francisco CA, US

International Classification:

C12Q 1/68
G01N 33/53
C07H 21/04
C12P 21/06
C12N 9/12

US Classification:

435006000, 435069100, 435194000, 435320100, 435325000, 536023200, 530388260, 435007100

Abstract:

The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the of PTK's and STK's have been identified and their protein structure predicted.